Genoway licenses CRISPR/Cas9 tech from ERS Genomics

By The Science Advisory Board staff writers

June 7, 2021 -- French company Genoway has entered a nonexclusive license agreement with ERS Genomics that grants Genoway past and future access to ERS Genomics' CRISPR/Cas9 patent portfolio.

Genoway is focused on the development of genetically engineered preclinical research models, specifically modified mice, rat, and cell lines. The license will allow the company to broaden its rodent model offerings.

Financial details of the agreement were not disclosed.

ERS Genomics, GenScript sign CRISPR/Cas9 license deal
ESR Genomics has agreed to nonexclusively license its CRISPR/Cas9 patent portfolio to GenScript.
ERS Genomics licenses gene editing tech to G+FLAS
ERS Genomics has signed a nonexclusive licensing deal granting G+FLAS Life Sciences access to its CRISPR/Cas9 patent portfolio.
Vivlion licenses CRISPR tech from ERS Genomics
Vivlion has signed a nonexclusive license agreement to access ERS Genomics' CRISPR/Cas9 patent portfolio to enhance Vivlion's gene editing reagents and...
ERS Genomics licenses gene editing tech to FASMAC
ERS Genomics, which has access to foundational CRISPR/Cas9 intellectual property co-owned by Emmanuelle Charpentier, has signed an agreement with FASMAC...
ERS Genomics inks licensing agreement with Applied StemCell
ERS Genomics said that it has signed a licensing agreement with Applied StemCell to commercialize CRISPR gene editing services and reagents.

Copyright © 2021

CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter